537In recent years there was considerable interest in the synthesis of conformationally restricted bioactive peptides [1 -3]. Due to the reduced flexibility of the peptide backbone these constrained structures are expected to possess improved potency, receptor subtype selectivity and enhanced resistance against proteolytic degradation. Besides other cyclization approaches backbone cyclization has been proven a promising concept for introducing conformational constraints on peptides without affecting the amino acid side chains [4]. To achieve N-backbone cyclization two amide nitrogens of the peptidic backbone have to be modified by alkylation. A variety of N-functionalized amino acids have been prepared and incorporated in peptide sequences [5 -9]. To circumvent difficult coupling steps during peptide synthesis using the solid phase methodology we have developed a method to introduce different types of N-functionalized dipeptide building units which are prepared in solution before their use in SPPS [10,11]. We were further interested in the application of the method of backbone cyclization to somatostatin analogues to probe our synthetic approach of incorporating preformed diAbstract. Somatostatin octapeptide analogues of the general sequence DPhe 5 -Phe 6 -Tyr 7 -DTrp 8 -Lys 9 -Val 10 -Phe 11 -Thr 12 -NH 2 containing two types of backbone cyclization have been synthesized by the solid phase methodology. Backbone cyclization in these peptides was achieved via N-modified phenylalanines in position 6 and 11. The N-modified amino acids were incorporated as dipeptide building units which have been prepared in solution prior to the solid phase synthesis. Two dipeptide units of structure a) Fmoc-aa 1 Ψ[CO-N((CH 2 ) n -X)]Phe-OH or b) Fmoc-aa 1 Ψ[CH 2 -N(CO(CH 2 ) n -X)]Phe-OH peptide units as well as to produce analogues with bioactivity, receptor subtype selectivity and enzymatic stability.The cyclic tetradecapeptide somatostatin (SST-14, SRIF) which was first isolated from ovine hypothalamus [12] is a potent inhibitor of endocrine and exocrine secretion of several hormones including growth hormone, glucagon, insulin and gastrin [13 -15]. It also regulates many other physiological activities and is considered an inhibitor of tumor cell growth [16] through binding to its specific cell surface receptors [17 -19]. Since SRIF and somatostatin-28, a 14 residues longer native form [13], bind to the five known receptors with low selectivity extensive structure-activity-studies have been carried out with a variety of synthetic analogues derived from small peptide structures [20 -22]. In both native peptides the Phe 7 -DTrp 8 -Lys 9 -Thr 10 -moiety has been disclosed as the pharmacophore sequence essential for biological activity of the molecule [20]. This core sequence allows further modifications and therefore a substitution of Phe 7 and Thr 10 by Tyr and Val, respectively, was found out to lead to biologically active comhave been introduced into the peptide sequence. Different resins and linkers were examined for an optimize...